Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been given an average recommendation of “Moderate Buy” by the five brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $17.25.

Several equities research analysts have commented on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $21.00 price target (down from $22.00) on shares of Enanta Pharmaceuticals in a report on Tuesday, November 26th. Robert W. Baird dropped their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, November 26th. Finally, HC Wainwright reduced their price target on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday.

Enanta Pharmaceuticals Stock Down 4.2 %

Enanta Pharmaceuticals stock opened at $6.10 on Thursday. The stock has a 50-day moving average price of $9.52 and a 200 day moving average price of $11.61. The company has a market capitalization of $129.28 million, a price-to-earnings ratio of -1.11 and a beta of 0.49. Enanta Pharmaceuticals has a 52 week low of $5.70 and a 52 week high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, November 25th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.20). The business had revenue of $14.60 million for the quarter, compared to analyst estimates of $17.99 million. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The business’s revenue was down 22.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.33) earnings per share. Research analysts anticipate that Enanta Pharmaceuticals will post -4.73 EPS for the current fiscal year.

Insider Transactions at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly sold 5,142 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total transaction of $41,444.52. Following the completion of the transaction, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at $6,461,202.28. This represents a 0.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 13.64% of the company’s stock.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Krensavage Asset Management LLC increased its stake in Enanta Pharmaceuticals by 19.7% during the 3rd quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock worth $15,520,000 after buying an additional 246,736 shares in the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Enanta Pharmaceuticals in the third quarter worth approximately $1,243,000. Point72 Asset Management L.P. purchased a new stake in shares of Enanta Pharmaceuticals during the third quarter worth approximately $903,000. Wellington Management Group LLP acquired a new position in Enanta Pharmaceuticals in the 3rd quarter valued at $360,000. Finally, State Street Corp raised its stake in Enanta Pharmaceuticals by 6.4% in the 3rd quarter. State Street Corp now owns 449,975 shares of the biotechnology company’s stock valued at $4,662,000 after purchasing an additional 27,147 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.